Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Studies Related to Vincristine‐Induced Peripheral Neuropathy in Chinese Pediatric ALL Patients
Clinical Pharmacology & Therapeutics · 2025-02 · 117 (2) · 454-464
DOI: 10.1002/cpt.3462 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 04.10.2024. Verfasst von Yawen Yuan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Phytogenic, Peripheral Nervous System Diseases, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Vincristine. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Vincristine (VCR) can cause vincristine‐induced peripheral neuropathy (VIPN) during the treatment of acute lymphoblastic leukemia (ALL) and the mechanisms are complicated. The aim of this study was to investigate the influencing factors on the population pharmacokinetics (PopPK) and pharmacodynamics (PD) related to VIPN, including clearance routes, drug–drug interactions (DDI), and genetic characteristics. Pediatric patients being treated for ALL were recruited to PK study where VCR and its metabolite (M1) were measured using a novel assay. The incidence of VIPN was also recorded. DNA sequencing of relevant PK and PD genes was performed. PopPK and PK/PD models were developed, pharmacogenetic and DDI analyses were conducted. In total, 79 children were recruited. The results showed that allometric scaling, ABCB1‐rs1128503 genotype, and posaconazole (POS) significantly improved the PopPK model fit. VIPN was significantly correlated with the exposure of VCR. Co‐administration with POS shifted the effect curve for VIPN to the left, indicating increased VIPN risk at the same exposure levels. No significant effects on VIPN were observed for CYP3A5 (rs776746), CYP3A4 (rs2242480), CEP72 (rs924607), or various ABCB1 variants (rs1128503, rs2032582, rs1045642, rs4728709, rs4148737, and rs10276036), nor with the co‐administration of fluconazole or dasatinib. In summary, co‐administration of POS increased VCR exposure by 0.4‐fold and raised the risk of VIPN, with an occurrence probability generally exceeding 0.7. Therapeutic drug monitoring of VCR in clinical practice may be necessary to enable appropriate dose adjustments and individualized treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Infection, Immunity, Inflammation Section, UCL Institute of Child Health, London, UK.
- Department of Hematology/Oncology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Department of Medical Genetics, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.
- Department of Clinical Pharmacy, School of Medicine, Xinhua Hospital, Shanghai Jiao Tong University, Shanghai, China.
ORCID-Profile: Yawen Yuan, Wenting Hu, Changcheng Chen, Ruen Yao, Shunguo Zhang, Xiao Zhu, Bulong Xu, Zhonghui Huang, Shengyuan Zhang, Xuexian Wang, Mei Zheng, Xiaohui Huang, Joseph F Standing
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yuan, Y., Hu, W., Chen, C., Yao, R., Zhang, S., Zhu, X., Xu, B., Huang, Z., Zhang, S., Wang, X., Zheng, M., Huang, X., & Standing, J. F. (2025). Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Studies Related to Vincristine‐Induced Peripheral Neuropathy in Chinese Pediatric ALL Patients. Clinical Pharmacology & Therapeutics, 117(2), 454-464. https://doi.org/10.1002/cpt.3462
Vancouver
Yuan Y, Hu W, Chen C, Yao R, Zhang S, Zhu X, et al. Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Studies Related to Vincristine‐Induced Peripheral Neuropathy in Chinese Pediatric ALL Patients. Clinical Pharmacology & Therapeutics. 2025;117(2):454-464. doi:10.1002/cpt.3462
BibTeX
@article{Yuan2025,
author = {Yuan, Yawen and Hu, Wenting and Chen, Changcheng and Yao, Ruen and Zhang, Shunguo and Zhu, Xiao and Xu, Bulong and Huang, Zhonghui and Zhang, Shengyuan and Wang, Xuexian and Zheng, Mei and Huang, Xiaohui and Standing, Joseph F},
title = {Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Studies Related to Vincristine‐Induced Peripheral Neuropathy in Chinese Pediatric ALL Patients},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
volume = {117},
number = {2},
pages = {454--464},
doi = {10.1002/cpt.3462}
}
EUVIMED